| Literature DB >> 29233828 |
Céline Vuillier1, Steven Lohard1, Aurélie Fétiveau1, Jennifer Allègre2, Cémile Kayaci2, Louise E King3, Frédérique Braun1, Sophie Barillé-Nion1, Fabien Gautier1,4, Laurence Dubrez2, Andrew P Gilmore3, Philippe P Juin5,4, Laurent Maillet5.
Abstract
E2F1 is the main pro-apoptotic effector of the pRB-regulated tumor suppressor pathway by promoting the transcription of various pro-apoptotic proteins. We report here that E2F1 partly localizes to mitochondria, where it favors mitochondrial outer membrane permeabilization. E2F1 interacts with BCL-xL independently from its BH3 binding interface and induces a stabilization of BCL-xL at mitochondrial membranes. This prevents efficient control of BCL-xL over its binding partners, in particular over BAK resulting in the induction of cell death. We thus identify a new, non-BH3-binding regulator of BCL-xL localization dynamics that influences its anti-apoptotic activity.Entities:
Keywords: BCL‐2 family; BCL‐xL mobility; E2F1; apoptosis
Mesh:
Substances:
Year: 2017 PMID: 29233828 PMCID: PMC5797968 DOI: 10.15252/embr.201744046
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 8.807